The prevalence of heart failure in patients with diabetes is four times higher than in the general population. Likewise, chronic kidney disease (CKD) and diabetes are common morbidities. As new drug classes emerge in the management of diabetes and heart failure and CKD, it is important to thoroughly evaluate available literature and identify opportunities to reduce complications and costs. Sotagliflozin is a first-in-class dual SGLT-1 and 2 inhibitor approved in Europe. Does it improve outcomes in patients with heart failure or CKD?
Guest Authors: Maren Richards Brinton, PharmD and Jonathan C. Hughes, PharmD, BCPS, BCACP
Music by Good Talk
Pulling Ahead After a SPRINT – Evidence for Lower Blood Pressure Goals
Televised Medical Talk Shows – Is There Truth in Edutainment?
Preventing Gestational Diabetes with Myo-Inositol: Ready for Prime Time?
An Aspirin a Day to Prevent Colon CA
The Heart of the Matter – Is EMPA-REG a Game Changer for Diabetes Management?
Taking a CHANCE on Clopidogrel Plus Aspirin to Prevent Stroke Recurrence
How Long Is Long Enough? Extending OAC After Unprovoked PE
Managing Direct Oral Anticoagulants – What’s Our Role?
PCSK9 Inhibitors: Blockbusters or Bust?
Short-Course Dexamethasone for Asthma Exacerbations in Children
CVD Risk Scores - Are They Accurate?
Folic Acid: A Simple Answer to a Very Large Problem?
Dressed for Success? Professional Attire and Patient Perceptions
Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?
Intensive Antiplatelet Therapy - Is Extended Therapy Worth It?
Co-trimoxazole+RAAS Inhibitors: A Deadly Combination?
Anticoagulation Bridge Therapy - Risks and Benefits Examined
Fish Oil for Rheumatoid Arthritis
Home-Based Primary Care: Can We Take These Results to the Bank?
Community Health Workers to Improve Asthma Outcomes
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive